The abundance of transcripts, or gene expression, in whole blood and its various cellular components is increasingly being investigated in the search for clinical diagnostic or prognostic markers. Changes in gene expression after in vitro exposure to a chemotherapy agent have also been explored in pharmacogenetic applications to try to associate such changes with the subsequent clinical response (1, 2 ) . Analyses of gene expression in various blood-derived samples have been explored for use in the diagnosis of septic shock (3, 4 ) , diagnosis of hypercoagulable states (5 ), posttraumatic injury prognostics (6 ) , and diagnosis of infection caused by different pathogens (7, 8 ) .
After completion of the human genome project, clinical applications of the transcriptome have been investigated by means of exploratory research with microarrays (9 ) . Such studies can quantify Ͼ30 000 transcripts in a single microarray and identify hundreds of potential markers that are differentially expressed between study groups and controls. In clinical practice, however, real-time PCR analyses will perform such molecular tests with reduced sets of transcripts. Only a handful of gene markers can be analyzed, and the expression of marker genes will be quantified against a reference (i.e., housekeeping) gene, by comparative C q methods (10 ) . Translation from exploratory research to clinical applications requires that a more limited set of marker genes be defined. Furthermore, QC methods, reference intervals, and the degrees of biological and analytical variation have to be established.
Similar to the assessments of routinely measured clinical analytes, several aspects of QC have recently been examined for gene expression, including sample processing (6, 11, 12 ) , preanalytical optimization and variation (13) (14) (15) , and effects of long-term storage (16 ) .
Further characterization of the potential utility of gene expression in blood samples requires data on the biological variation in the marker genes. Such data are useful in QC and for selecting the most informative marker genes from a large group of differentially expressed candidate genes identified in exploratory studies. Gene expression analysis is not clinically useful unless such variation data are available (17, 18 ) .
Recently, Peters et al. examined interindividual and intraindividual variation in gene expression in blood samples (19 ) . They used standardized reverse transcription-PCR analysis to measure the expression of 19 marker genes. Interindividual variation accounted for almost half of the total variance and was the major component of biological variation; however, the magnitude of the interindividual variation in these 19 marker genes varied over a 4-fold range, with CVs ranging from 10% to 40%. Markers with lower interindividual variation were more informative than those with high variation and had a higher individuality index (17, 19 ) .
Although differences in gene expression across the entire transcriptome and mechanisms of regulation are important topics in the field of genetics, the available reports have examined only a limited number of genes. Early studies suggested that expression differences were partly due to inherited genetic polymorphisms (20 ) , and several genome-wide studies have been performed to associate differences in gene expression to sequence variation in the genome (21, 22 ) . Although these studies were designed to address the genetic mechanism leading to interindividual variation, they also provided high-quality data sets regarding genomewide expression for a large sample of individuals (20, 22 ) . We have analyzed one such set (22 ) of wholegenome gene expression data covering Ͼ30 000 gene transcripts. Our study of the gene expression profiles of 270 lymphoblastoid cell lines derived from volunteer donors yielded expression data for Ͼ10 000 transcripts. Our results provide insight into the interindividual variation of genes expressed in the hematolymphoid lineage and are most readily extrapolated to gene expression in blood samples.
Materials and Methods
The Wellcome Trust Sanger Institute (http://www. sanger.ac.uk/) provided genome-wide expression profiles for 270 HapMap lymphoblastoid cell lines derived from individuals of 4 ethnic groups, and we further analyzed data from 210 unrelated individuals (60 Africans, 60 Caucasians, 45 Chinese, and 45 Japanese). The data set contained 4 replicates of each cell line and was analyzed on the Sentrix® Human-6 Expression BeadChip (Illumina). This array quantifies the expression of approximately 47 000 different transcripts. Values of expression intensity were normalized on a logarithmic scale with a quantile normalization method (22 ) . Because the hematolymphoid lineage did not express all transcripts, we used an arbitrary threshold of intensity (mean raw intensity Ͼ100) to filter out genes with low or absent expression. The filtering process retained 11 355 transcripts for analysis, representing 10 749 different genes or unique transcripts.
The analysis of variance was similar to that previously described by Peters et al. (19 ) . The available information (sex, ethnic group) for the cell lines was used to partition total variation into interindividual, interethnic group, and residual components. Partitioning of variance components was carried out with a nested multilevel model. Variances were partitioned in a nested model in the following order: (a) inter-ethnic group CV (CV e ) 4 , (b) interindividual CV (CV g ), and (c) residual (analytical) CV among the 4 replicates. In this multilevel model, the effect of sex on gene expression was taken as a fixed effect. The log-transformed intensity values of each transcript were used, and the parameters of the nested model were determined with the NLM module in the R statistical package (23 ) . Fig. 1A summarizes the relative expression of transcripts across the entire genome (11 355 genes). The distribution is skewed, with raw expression intensities most commonly occurring in the range of 10 2 -10 3 (i.e., values of 2-3 on a log 10 scale), and highly expressed genes (expression intensities Ͼ10 4 ) were few. The range of expression intensities covered more than 3 orders of magnitude.
Results

RELATIVE GENE EXPRESSION AND VARIANCES ACROSS
THE GENOME
IDENTIFICATION OF GENES WITH THE LEAST BIOLOGICAL
VARIANCE
Assessments of CV g and CV e indicated that these components contributed to the total biological CV (CV b ). In general, highly expressed genes have lower CV b val-ues (Fig. 1B) . Table 1 lists genes according to transcript expression in order of increasing CV b value.
An examination of Table 1 shows that most of the genes with high expression values (Ͼ10 4 ) that show promise as reference genes with very low variation are those that encode ribosomal proteins. This list also includes commonly used reference genes, such as those encoding ␤-actin and ␤ 2 -microglobulin (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol55/issue4).
Reference genes of intermediate expression are commonly involved in one of 2 cellular processes: (a) respiration (mitochondrial proteins or enzymes in the respiratory chain), or (b) transcription and processing of mRNA (such as components of the splicing machinery). On the other hand, reference genes expressed at low levels (10 2 -10 3 ) showed no apparent functional prevalence. These low-expression reference genes have functions in a variety of processes, such as apoptosis, cell signaling, and the immune response. Fig. 2 and Table 2 show the relationship between the 2 types of biological variation, CV g and CV e . In general, the variation in gene expression within an ethnic group (i.e., CV g ) was higher than variation across ethnic groups (CV e ). Therefore, the majority of the points fall on the plot beneath the line of identity (slope ϭ 1, y intercept ϭ 0). The atypical genes that showed high ethnic differentiation lie above the line of identity.
TRANSCRIPTS WITH HIGH CV g
Genes with low CV values in both dimensions (i.e., lower-left corner of Fig. 2 ) are reference genes. At the other extreme are genes with high CV g values (open squares in Fig. 2 ; Table 2 ). The highest CV g value (38%) was for a gene in major histocompatibility complex (MHC) class II, HLA-DQA1 5 (major histocompatibility complex, class II, DQ alpha 1). Interestingly, 4 other genes in MHC class II also showed high CV g s [HLA- 5 Human genes: HLA-DQA1, major histocompatibility complex, class II, DQ alpha 1; HLA-DQA2, major histocompatibility complex, class II, DQ alpha 2; HLA-DRB1, major histocompatibility complex, class II, DR beta 1; HLA-DRB3, major histocompatibility complex, class II, DR beta 3; HLA-DRB5, major histocompatibility complex, class II, DR beta 5; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; UGT2B17, UDP glucuronosyltransferase 2 family, polypeptide B17; CXCL10, chemokine (C-X-C motif) ligand 10; UGT2B7, UDP glucuronosyltransferase 2 family, polypeptide B7; UGT2B11, UDP glucuronosyltransferase 2 family, polypeptide B11; UTS2, urotensin 2; ACTB, actin, beta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RPL19, ribosomal protein L19; RPL32, ribosomal protein L32; RPL11, ribosomal protein L11; RPS18, ribosomal protein S18; UBE2D2, ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast); HPRT1, hypoxanthine phosphoribosyltransferase 1; HLA-DRA, major histocompatibility complex, class II, DR alpha; HLA-DMA, major histocompatibility complex, class II, DM alpha; HLA-DMB, major histocompatibility complex, class II, DM beta. span a 2-fold range. Therefore, the individuality index, which is inversely proportional to CV g , will be low, and the reference intervals for these genes will be wide. Showing high variation in expression were several enzymes encountered in pharmacogenetics, in- cluding GSTM1 (glutathione S-transferase mu 1), GSTT1 (glutathione S-transferase theta 1), and UGT2B17 (UDP glucuronosyltransferase 2 family, polypeptide B17). In addition, CXCL10 [chemokine (C-X-C motif) ligand 10], an important chemokine that is induced by interferon ␥, also had a high CV g . Table 2 in the online Data Supplement lists other genes with intermediate CV g s (10%-15%). More important are the genes with low CV g values that are not reference genes, because they have the potential to become ideal biomarkers. The genes listed in Table 3 in the online Data Supplement have transcript CV g s in the lowest quartile; they are potential preferred biomarkers of gene expression.
GENE TRANSCRIPTS WITH HIGH CV e
For the vast majority of genes, CV e is less than CV g ; however, there are some exceptions. Table 3 lists genes with CV e s both Ͼ8% and greater than the CV g ; these genes are plotted as ϫ symbols in Fig. 2 . Three of the genes [UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptides B7), UGT2B11 (UDP glucuronosyltransferase 2 family, polypeptides B11), and UGT2B17] encoded transcripts for pharmacogenetically or metabolically important enzymes. The signals for 2 probes for sequences in UTS2 (urotensin 2) confirmed the high interethnic variation for this gene.
Discussion
This study is the first attempt on a whole-genome scale to examine interindividual and interethnic variation in gene expression with a perspective toward testing in the clinical laboratory. The past 5 years have witnessed an increasing number of laboratory applications of gene expression analysis for blood samples. The most prominent application is the diagnosis of early septic shock with prognostic application in critically ill patients (24 -26 ) . Furthermore, gene expression analysis has also been used as a tool to detect circulating tumor cells (27, 28 ) . Both applications rely on robust gene expression analysis performed at a high level of QC. Biological variation has been well documented for most common analytes in routine clinical use. The typical magnitude of the variation is often determined early during development and validation of the assays; however, examination of biological variation in gene expression has not been performed on a large scale for Table 2 . Atypical transcripts with CV e values greater than CV g are also indicated (ϫ) and are listed in Table  3 . Ideal biomarkers should have a low CV g (for example, CV g below the lower quartile value, i.e., Ͻ2.25%).
blood samples or for cells of the same lineage. In this study, we have used a collection of hematolymphoid cell lines derived from 210 individuals of different ethnic backgrounds to examine such variation. This genome-wide analysis provides some new insights into genes with different degrees of biological variation. Such information is essential for developing biological markers for disease diagnosis or prognostication.
REVIEW OF COMMONLY USED REFERENCE GENES
In most clinical applications of quantifying gene expression, the expression of a marker gene is compared with that of a reference gene that is stably expressed among individuals (10, 29 ) . Various genes have been proposed as references (30 -33 ) . Table 1 in the online Data Supplement lists some of the most frequently used reference genes. ACTB (actin, beta) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) are the most commonly used reference genes. Our results confirmed that the ACTB gene is a good reference candidate. As others have reported (34 ) , however, we found GAPDH expression to be more variable than expected. We therefore recommend that this gene not be used in a study as the only reference gene (33, 35 ) . We also confirmed that good reference genes showing stable expression include a group encoding ribosomal proteins, some of which others have used (32 ) . We note, however, that 2 such genes, RPL19 and RPL32 (ribosomal proteins L19 and L32), showed some degree of interethnic variation. Therefore, 2 other ribosomal protein genes, RPL11 (ribosomal protein L11) and RPS18 (ribosomal protein S18), may be better choices.
The genes for all these ribosomal proteins and well-established reference genes (e.g., ACTB) are all expressed at the highest range of expression, Ͼ10
4
. Although they may be adequate for controlling most aspects of technical errors, such as efficiencies of RNA extraction and reverse transcription, they may not be the best normalization genes for marker transcripts produced at lower concentrations (30, 36 ) . The best approach would be to use reference genes for normalization that are expressed at the same order of magnitude as the markers of interest. The currently used reference genes with low to moderate expression (i.e., mean expression intensity at 10 2 -10 3 ) all show some degree of variation, with a CV g as high as 4.5% for UBE2D2 [ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast)], for example. Furthermore, HPRT1 (hypoxanthine phosphoribosyltransferase 1), another well-known and moderately expressed reference gene, might have a sex-biased expression (P ϭ 0.03 for a sex effect), given that it is located on the X chromosome. Transcripts of such genes are not ideal for normalization of the expression of diseaseassociated marker genes. We recommend that the genes in Table 1 with low or moderate expression be further evaluated as reference genes.
INTERINDIVIDUAL VARIATION ACCOUNTS FOR THE MAJOR
COMPONENT OF BIOLOGICAL VARIATION IN GENE EXPRESSION, BUT INTERETHNIC VARIATION MAY ALSO BE IMPORTANT
Interindividual variation is the most important component of genetic differences in the population. The same conclusion was reached recently in an evaluation of QC parameters in a setting of clinical laboratory tests (19 ) . Almost half (43%) of the total variation was due to interindividual variation. These results demonstrate the necessity of characterizing interindividual variation before translating laboratory tests of gene expression into clinical practice. Spielman et al. (37 ) used a different approach in a study of 142 lymphoblast cell lines from ethnic groups across 2 continents (Chinese and Japanese vs Caucasians). The investigators identified 35 genes with significantly different expression in the 2 main ethnic groups. Although both the statistical methods and the microarray chip used for expression profiling were different from those of our study, 2 (22%) of 9 genes in our Table 3 are in common with the genes in their list (37 ) . We analyzed 11 355 transcripts of hematolymphoid cell lines from 210 individuals from several ethnic groups to quantify the variation in gene expression and confirmed that CV e was greater than CV g for fewer than 4% (427) of the transcripts. This result suggests that different reference intervals may be necessary for different ethnic groups for certain transcripts if they become useful as markers. 
SELECT MARKER GENES WITH LOW CV g VALUES FOR CLINICAL
APPLICATIONS
In searching for clinically useful biomarkers among a group of differentially expressed genes, it is important to consider the biological variation due to CV g and that due to a clinically relevant phenotype or response (CV r ). For a marker gene to be effective at differentiating clinically important groups, it must show large between-group variation (i.e., a high CV r ) but a low CV g within each of the groups; that is, the preferred biomarker would be the one with a high CV r -to-CV g ratio. A potential biomarker with a low CV g is better than other genes with high CV g s that measure a similar clinical phenotype or response. A classic example is the comparison of serum creatinine with cystatin C in the assessment of renal function (17 ) . It is well known that a large decrease in the glomerular filtration rate is required before the serum creatinine concentration increases above the upper reference limit for the population. Compared with cystatin C, the CV r -to-CV g ratio is much lower for serum creatinine because of this marker's large interindividual variation (17 ) .
At the stage of exploratory research into a clinically important response, multiple genes may be found to be differentially expressed in patients and control individuals, and such investigations are usually carried out in microarray experiments. From the hundreds of differentially expressed candidates, a few gene markers will then need to be chosen for translational research in order to further characterize their clinical utility, usually by real-time quantitative PCR analyses. An appropriate process of marker selection is therefore required at this stage. Genome-wide data that document interindividual variation can play an important role in prioritizing gene markers for further evaluation.
The example of prognosis prediction in septic shock patients illustrates the potential of the use of interindividual variation for prioritizing candidate gene markers. Pachot et al. (3 ) studied the expression of MHC class II genes in whole blood from patients with septic shock and compared expression levels in survivors and nonsurvivors. The investigators reported a generalized down-regulation of genes at MHC class II loci during the course of septic shock; nonsurvivors had even greater suppression of these genes (3 ). Subsequent publications confirmed this phenomenon (38, 39 ) . Survivors and nonsurvivors showed differential expression of many MHC class II genes (CV r ), including HLA-DRA (major histocompatibility complex, class II, DR alpha), HLA-DRB1, HLA-DMA (major histocompatibility complex, class II, DM alpha), and HLA-DMB (major histocompatibility complex, class II, DM beta), and it was not certain which would be the preferred marker genes for clinical applications. We examined CV g for these genes (Table 4) . HLA-DRB1 clearly had a very high CV g (19%) compared with other genes (even across the entire genome). As mentioned above, biomarkers with a narrow reference interval and a high CV r -to-CV g ratio are preferable. Accordingly, HLA-DRB1 would not be a good marker because it has a low CV r -to-CV g ratio owing to its high CV g ; therefore, the other 3 markers with similar CV g s are preferred. In fact, HLA-DMB was found to predict survival at both early and late time points (3 ).
LIMITATIONS
We quantified interindividual variation in gene expression under a situation in which environmental effects were kept to minimum, i.e., cell lines were raised and grown in an identical medium and environment. To fully characterize the biological variation of an analyte requires measurement of both interindividual variation and intraindividual variation to determine individuality indices and reference interval values (17, 18 ) . These parameters are all essential for characterizing the clinical utility of a laboratory test; however, such a highly controlled environmental setting does not allow a complete examination of intraindividual variation. Therefore, the values for the variation parameters we have presented represent estimates of the lower limits of the true parameter values. Having said that, we did observe large differences in interindividual variation across the genome. As illustrated in the example of 
Conclusion
This genome-wide analysis of CV g for hematolymphoid gene transcripts has demonstrated large biological variation in gene expression across the whole genome. Our results are useful for prioritizing marker genes during the translation of exploratory research to the clinical application of gene expression markers. 
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